ReShape Dual Balloon Enters U.S. Market, Headlining Week Of Obesity Device News
This article was originally published in The Pink Sheet Daily
Executive Summary
It was a banner day for minimally invasive weight-loss devices July 28. FDA approved ReShape Medical's intragastric balloon and Aspire Bariatrics submitted an application for its AspireAssist aspiration therapy system for obesity. Two days later, GI Dynamics announced the termination of a pivotal study for its Endobarrier device.